Year All2024202320222021202020192018201720162015201420132012201120102007 11.21.22 Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference WALTHAM, Mass. , Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Read More 11.03.22 Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update – Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1 months – – Enrollment complete in pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD – – Company remains on track for two U.S. Read More 11.03.22 Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias - 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events - - Median duration of CR/CRh response of 9.1 months - - 9 of 12 patients who underwent stem cell transplant after achieving a response Read More 10.27.22 Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022 WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2022 financial results and provide a business update on Read More 08.08.22 Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update – On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 – – Updated data from Phase 1 portion of AUGMENT-101 trial expected in 4Q22 – – Company to host conference call today at 4:30 p.m. ET – WALTHAM, Mass. , Aug. Read More 08.02.22 Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2022 financial results on Monday, August 8 , after the Read More 06.13.22 Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer WALTHAM, Mass. , June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Read More 05.26.22 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two Read More 05.11.22 Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day WALTHAM, Mass. , May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More 05.09.22 Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing revumenib (SNDX-5613) in combination with venetoclax-azacitidine for newly diagnosed patients and Read More 05.02.22 Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results Read More 03.01.22 Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in 1H23 - - Initiation of three new trials of SNDX-5613 in NPM1 and MLLr acute leukemias, including in the first-line and maintenance settings, expected in 1H22 - - Company to host Read More
11.21.22 Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference WALTHAM, Mass. , Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Read More
11.03.22 Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update – Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1 months – – Enrollment complete in pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD – – Company remains on track for two U.S. Read More
11.03.22 Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias - 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events - - Median duration of CR/CRh response of 9.1 months - - 9 of 12 patients who underwent stem cell transplant after achieving a response Read More
10.27.22 Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022 WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2022 financial results and provide a business update on Read More
08.08.22 Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update – On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 – – Updated data from Phase 1 portion of AUGMENT-101 trial expected in 4Q22 – – Company to host conference call today at 4:30 p.m. ET – WALTHAM, Mass. , Aug. Read More
08.02.22 Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2022 financial results on Monday, August 8 , after the Read More
06.13.22 Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer WALTHAM, Mass. , June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Read More
05.26.22 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two Read More
05.11.22 Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day WALTHAM, Mass. , May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More
05.09.22 Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing revumenib (SNDX-5613) in combination with venetoclax-azacitidine for newly diagnosed patients and Read More
05.02.22 Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results Read More
03.01.22 Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in 1H23 - - Initiation of three new trials of SNDX-5613 in NPM1 and MLLr acute leukemias, including in the first-line and maintenance settings, expected in 1H22 - - Company to host Read More